LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Haleon Plc

4.00 (1.24%)
Share Name Share Symbol Market Type Share ISIN Share Description
Haleon Plc LSE:HLN London Ordinary Share GB00BMX86B70 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  4.00 1.24% 325.65 3,695,203 14:56:02
Bid Price Offer Price High Price Low Price Open Price
325.55 325.70 326.30 321.20 321.70
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Offices-holdng Companies,nec 10,858.00 1,156.30 1,252.10 24.74 30,072.39
Last Trade Time Trade Type Trade Size Trade Price Currency
14:56:02 AT 509 325.65 GBX

Haleon (HLN) Latest News

Haleon (HLN) Discussions and Chat

Haleon Forums and Chat

Date Time Title Posts

Add a New Thread

Haleon (HLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Haleon (HLN) Top Chat Posts

Top Posts
Posted at 12/5/2023 08:04 by zho
GSK PLC GSK completes sale of shares in Haleon plc

Further to the announcement by GSK on 11 May 2023, GSK has agreed to sell 240m ordinary shares in Haleon plc (" Haleon ") at a price of 335 pence per share (the " Placing Shares "), raising gross proceeds of approximately GBP804m (the " Placing ").

Following settlement of the Placing, GSK will hold 955m(1) ordinary shares in Haleon, representing approximately 10.3% of the issued share capital of Haleon.

GSK and Pfizer Inc. (which holds a 32% stake in Haleon), have each undertaken not to dispose of any further shares in Haleon for a period of 60 days following settlement of the Placing, subject to certain customary exceptions and waiver by BofA Securities.

Posted at 13/2/2023 21:15 by bobo18 according to stockopedia....Makes more sense - £2.6 bio expected profit fr 2022 - market cap £30 bio...Q4 looks to be better with all the cold and flu outbreaks - hot market for them, so they certainly aren't expensive at 3.30.I always look back to Unilever looking to pay £50bio just two/three years ago.....
Posted at 12/2/2023 15:08 by netcurtains
HLN dont make mustard or plastic buckets either.
Posted at 26/1/2023 09:27 by tradermichael
Yes anhar, (Haleon releases its fourth quarter and final year 2022 results on 2nd March). Credit Suisse predict organic sales growth of 3.7% and OTC growth of 5.0%.

On an earnings discount to European rivals, 'outperform' is the investment rating with a share price target of 376p.

Posted at 14/10/2022 09:58 by anhar
I have no idea of the future share price of HLN but it's odd how the price has been rising lately in view of your repeated bearish comments.

If you really are interested in what brokers and press etc. think, you need to check out all of them and see what the balance of their opinion is, not just cherry pick those that agree with your predetermined view. That's called confirmation bias and is one of the large range of classic small investor mistakes.

I personally have no interest in such views but make up my own mind, which is that on balance HLN is more worth keeping than selling now.

Posted at 12/10/2022 04:55 by paul planet earth
'Wallet Investor’s Haleon long-term forecast indicated that the stock could be a non-viable investment. The algorithm-based forecasting service predicted that the share price could fall to £2.21 by the end of 2022 and decline throughout 2023 to trade at just £0.09 by the end of the year. The stock could effectively fall to zero by 2024, according to WalletInvestor’s forecast for the Haleon stock price in 5 years.

The Haleon stock 5-year forecast from Gov Capital similarly estimated that the American Depositary Receipts (ADRs) for Haleon listed in the US could drop to zero, but by November 2023.'

The most likely scenario is that due to the impact of generic drug labels, rising consumer inflation, and multi billion dollar Zantac litigation costs and settlements the share price will fall. The high burden of existing debt, rising interest rates, and flattening consumer sales reflected in the falling share price, note the price is down 16% since floatation with the expected off loading of both Pfizer and GSK's share holdings in November places more downward pressure on the share price on the foreseeable future.


Posted at 07/10/2022 10:31 by anhar
Strange how the share has been rising in recent weeks, given that the lock-in overhang from GSK and PFE is public knowledge and has been ever since the demerger details were released months ago.

I don't have the faintest idea of the manner in which they might dispose of their HLN shares and how it might affect the share price, but it just seems odd that if you are correct with your repetitive assertions about a price crash driven by big sales, why would the price be rising now?

Big cap share prices are driven by institutional trading, small private investors like us are irrelevant. So the rising price must be driven by inst buying on balance. Why would that be if it is feared that the price would soon collapse? Surely, if your view proves anywhere near accurate, they would be better waiting for the big HLN price crash you keep mentioning. In other words their opinions must be virtually the exact opposite of yours. I''m not saying that insts are always right, they're often wrong, but it does appear odd in this situation where there's only a few weeks at stake.

My view is that any potential big price fall is already in the price so there is little to fear. In any case, personally I hold shares very long term so I'm hanging on to my HLN allocation as it may prove to be a good share in years to come. Short term fears like you keep stating are of no concern to me and even if you're right, I'd see it as a buying opportunity and nothing to worry about. Nobody is going to care in several years time about a historical GSK/PFE overhang.

Posted at 18/9/2022 11:39 by paul planet earth
FX rate 1.14 what happens to a GBP share price when Sterling eventually strengthens versus Dollar!..another 10% off the share price less Sterling denominated earnings!
Posted at 20/8/2022 07:57 by paul planet_earth
IMO I suspect Zantac and what we are seeing now is just the tip of the iceberg..

GSK and Pfizer will have to sell their share holdings in Haleon to fund US litigation costs running into the billions despite their deniels pushing the Haleon share price to new lows..

Haleon as the OTC historic seller will face both direct claims and those from either GSK and Pfizer in the form of historic indemnities for selling the drug in the past..

Haleon is already heavily indebted with £10 billion of debt handed over from GSK...Facing billions in US litigation fines and legal costs it will either need a rights issue where new investors have no stomach for or enter a brand fire sale..

Haleon share price will tumble to new lows sub 200p by which point the business will be worth only a third of what Unilever offered back in December and I suspect as the Zantac clouds slowly clear will be snapped up by a larger rival Nestle, Reckitt, Unilever and asset stripped and vanish to be remembered as just a brief historic footnote on its epitaph!

As always DYOR!

Posted at 12/8/2022 10:46 by careful
Perfect market theory assumes that every share price is at the correct level a given time because the market adjusts for known events.

So todays share price is correct after this weeks gloomy worst case scenario panic about the litigation.
This is why research shows that a monkey throwing darts can select a successful share portfolio as well as the shrewdest investor.

It is random.
I will hold assuming that todays share price is neither cheap nor expensive until things become clearer after this panic.

Really we should check in 5 years time, but we are all idiots watching every day.

Haleon share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 14:11:46